FDA Accepts NDA for TLX101-Px (Pixclara®)
Melbourne (Australia) and Indianapolis (United States) | April 10, 2026
Telix today announces that the United States (U.S.) Food and Drug Administration (FDA) has accepted the Company’s resubmitted New Drug Application (NDA) for TLX101-Px[1], (Pixclara®[2], Floretyrosine F 18 or 18F-FET), an investigational PET[3] agent for the imaging of glioma (brain cancer), and has assigned a PDUFA[4] goal date of September 11, 2026.
The approval of TLX101-Px will fulfil a significant unmet medical need for the characterization of recurrent or progressive glioma from treatment related changes in both adult and pediatric patients[5]. Neuroimaging of glioma with 18F-FET is already broadly recommended in international clinical practice guidelines – including NCCN Guidelines®[6] – and TLX101-Pxhas been granted Orphan Drug[7] and Fast Track[8] designations by the FDA.
“There remains a critical unmet need in improving our ability to image residual glioma after treatment,” said Thomas Hope, MD, Vice Chair, Department of Radiology and Biomedical Imaging, University of California, San Francisco (UCSF). “We have worked with Telix for the last three years to help leverage our clinical data to help make FET-PET[9] available to patients in the United States.”
Patrick Wen, MD, E. Antonio Chiocca, MD, PhD, Family Endowed Chair in Neuro-Oncology at Mass General Brigham Cancer Institute, added, “Distinguishing tumor progression from treatment-related change remains one of the most challenging aspects of glioma care. PET imaging with 18F-FET is an important tool in clinical practice worldwide, and the FDA’s acceptance of this application is a meaningful step toward broader access for patients and clinicians in the United States.”
Kevin Richardson, CEO, Telix Precision Medicine, added, “The FDA’s acceptance of our NDA resubmission is an important milestone for Telix. We appreciate the FDA’s constructive engagement and look forward to working closely with the Agency to urgently obtain approval and then bring this product to market for the benefit of patients.”
No revenue from Pixclara is included in Telix FY 2026 revenue guidance.
About TLX101-Px
TLX101-Px is a PET imaging candidate, which has been granted Fast Track and Orphan Drug designations by the FDA for the characterization of recurrent or progressive glioma from treatment related changes. TLX101-Px targets membrane transport proteins known as L-type amino acid transporters 1 and 2 (LAT1 and LAT2). This enables TLX101-Px to be potentially utilized as a patient selection and response assessment tool for Telix’s LAT1-targeting therapy candidate TLX101-Tx (iodofalan 131I), currently under investigation in the pivotal IPAX-BrIGHT trial in patients with recurrent glioblastoma[10]. TLX101-Px and TLX101-Tx have not received marketing authorizations in any jurisdiction.
About gliomas
Gliomas are diffusely infiltrative tumors that affect the surrounding brain tissue. They are the most common form of central nervous system (CNS) cancer that originates from glial cells, accounting for approximately 30% of all brain and CNS tumors and 80% of all malignant brain tumors[11]. In the U.S., there are approximately 24,000 new glioma cases diagnosed annually[12]. Glioblastoma (GBM) is a high-grade glioma and the most common and aggressive form of primary brain cancer. The mainstay of treatment for GBM comprises surgical resection, followed by combined radiotherapy and chemotherapy. Despite such treatment, recurrence occurs in almost all patients[13], with an expected survival duration of 12-15 months from diagnosis[14].
TLX101-Tx and TLX101-Px have not received marketing authorizations in any jurisdiction.
[1] Telix’s NDA was resubmitted on March 13, 2026. Telix ASX disclosure March 16, 2026.
[2] Brand name subject to final regulatory approval.
[3] Positron emission tomography.
[4] Prescription Drug User Fee Act.
[5] Subject to FDA review and approval.
[6] Galldiks et al. Lancet Oncol. 2025 (Joint guidelines from the European Association of Nuclear Medicine (EANM), European Association of Neuro-Oncology (EANO), Society of Nuclear Medicine and Molecular Imaging (SNMMI), Response Assessment in Neuro-Oncology (RANO), The European Society for Pediatric Oncology and The Response Assessment in Pediatric Neuro-Oncology for the characterization of recurrence in glioma patients); National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Central Nervous System Cancers V1.2025.
[7] Telix ASX disclosure October 6, 2020.
[8] Telix ASX disclosure April 16, 2024. Fast Track is a process designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need. The purpose is to get important new drugs to the patient earlier. More: https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/fast-track
[9] Positron emission tomography imaging with Floretyrosine F 18.
[10] ClinicalTrials.gov ID: NCT07100730.
[11] Goodenberger et al. Cancer Genet. 2012.
[12] CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2018-2022. Neuro-Oncology. 2025.
[13] Park et al. Journal of Clinical Oncology. 2010.
[14] Ostrom et al. Neuro Oncol. 2018.